Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

Adjei AA, Christian M, Ivy P (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866–1872

Beeram M, Patnaik A, Rowinsky EK (2005) RAF a strategic target for therapeutic development against cancer. J Clin Oncol 23: 6771–6790

Berardi R, Scartozzi M, Freddari F, Squadroni M, Santinelli A, Bearzi I, Fabris G, Cascinu S (2006) Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. Cancer Treat Rew 32: 333–347

Clark JW, Meyerhardt JA, Sahani DV, Namasivayam S, Abrams TA, Stuart K, Bhargava P, Blaszkowsky LS, Jain SR, Zhu AX (2007) Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. J Clin Oncol 25: 18S (Suppl; abstract 4625)

Dal Lago L, D’Hondt V, Awada A (2008) Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumor. Oncologist 13: 845–858

de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341: 1368–1378

Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96: 896–902

El-Khoureiry AB, Rankin C, Lenz HJ, Philip P, Rivkin SE, Blanke CD (2007) SWOG 0514: a phase II study of sorafenib (BAY43-9006) as single agent in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 25: 18s: 4639

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF (1996) Outcome of treatment for distal bile duct cancer. Br J Cancer 83: 1712–1715

Fong Y, Kemeny N, Lawrence TS (2001) Cancer of the liver and biliary tree. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellmam S, Rosenberg SA (eds), pp 1178–1203. Lippincott-Raven: Philadelphia (PA)

Furuse J, Okusaka H, Miyazaki M, Taniai H, Nimura N, BT22 Study Group (2009) A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary tract cancer. J Clin Oncol 27: 15s, (Suppl; abstract 4579)

Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. The Oncologist 13: 415–423

Huether A, Hopfner M, Baradari V, Schuppan D, Scherübl H (2007) Sorafenib alone or in combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 73: 1308–1317

Iyer RV, Gibbs J, Kuvshinoff B, Fakih M, Kepner J, Soehnlein N, Lawrence D, Javle MM (2007) A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14: 3202–3209

Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, Hayashi K, Mosher DF, Sugimachi K, Tsuneyoshi M, Kuwano M (1998) Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 28 (6): 1512–1517

Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27 (10): 1675–1684

LaRocca RV, Hicks MD, Foreman B (2007) Effective palliation of advanced cholangiocarcinoma with sorafenib: a two patient case report. J Gastrointest Cancer 38: 154–156

Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51: 349–364

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008a) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials (2008b) Design and endpoints of clinical trials in hepatocellular carcinoma. J Nat Cancer Inst 100: 698–711

Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS (2008) Phase II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 53: 564–570

Strumberg D, Richly H, Hilger RA, Scleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965–972

Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706–712

Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61: 535–548

Thongprasert S, Napapan S, Charoentum C, Moonprakan S (2005) Phase II study of gemcitabine and cisplatin as first line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16: 279–281

Valle JW, Wasan HS, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton M, Bridgewater JA (2009) Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol; 27: 15s (Suppl; abstract 4503)

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64: 7099–7109